Transformational Period for AGL27 Sep 2015 19:10
After what seems like an eternity we are finally entering a transformational period for AGL, each and every KOL has endorsed Parsortix, we have our first Translational data from Vienna and now our first peer review published by Barts. The Ovarian trial is about to commence and research sales are on track to start before the end of this calendar year, both of these events should see significant uplift in the SP IMO, as we become a clinical stage commercial enterprise.